Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
Creates a reciprocal marketing approval pathway for certain drugs, biological products, and devices already lawfully marketed in specified foreign countries or the United Kingdom.
Who Benefits and How
Manufacturers and sponsors of eligible products could gain a faster path into the U.S. market, and patients could gain faster access to products with unmet-need value.
Who Bears the Burden and How
The FDA would have to evaluate reciprocal-approval requests quickly, negotiate labeling, and manage denials and postmarket conditions under the new system.
Key Provisions
- Creates a reciprocal marketing approval pathway for eligible foreign-authorized drugs, biologics, and devices.
- Requires FDA decisions within 30 days, subject to congressional disapproval rules and possible postmarket study conditions.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Creates a reciprocal marketing approval pathway for certain drugs, biological products, and devices already lawfully marketed in specified foreign countries or the United Kingdom.
Key Policy Areas
Healthcare, Trade
Primary Purpose
Creates a reciprocal marketing approval pathway for certain drugs, biological products, and devices already lawfully marketed in specified foreign countries or the United Kingdom.
Policy Domains
Main Provisions
Identified Gains
Contextual inference, no direct clause citation- Sponsors of eligible foreign-authorized drugs, biologics, and devices
- Patients seeking faster access to unmet-need products
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- FDA officials required to administer the reciprocal approval pathway
Contextual inference, no direct clause citation
Sponsors
Ted Cruz
R-TX | Primary Sponsor
Legislative Progress
In CommitteeMr. Cruz (for himself and Mr. Lee) introduced the following …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Sponsors of eligible medical products seeking reciprocal U.S. marketing approval
FDA officials reviewing reciprocal approval requests on an accelerated timetable
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology